Stoke Therapeutics (NASDAQ:STOK) Announces Earnings Results

Stoke Therapeutics (NASDAQ:STOK) issued its quarterly earnings results on Tuesday. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05, Zacks reports. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The company had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million.

Stoke Therapeutics Trading Up 0.2 %

NASDAQ:STOK traded up $0.02 during trading hours on Thursday, hitting $13.27. 407,546 shares of the company traded hands, compared to its average volume of 761,397. Stoke Therapeutics has a twelve month low of $3.77 and a twelve month high of $17.58. The stock has a market capitalization of $698.64 million, a price-to-earnings ratio of -6.09 and a beta of 0.95. The firm has a 50-day moving average of $13.24 and a 200 day moving average of $13.70.

Analyst Ratings Changes

A number of analysts recently commented on STOK shares. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Wedbush restated an “outperform” rating and set a $17.00 price target on shares of Stoke Therapeutics in a report on Thursday, July 11th. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Finally, Leerink Partners initiated coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $20.83.

Insider Activity

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the transaction, the insider now owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 11.30% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.